This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Celgene
ClinicalTrials.gov Identifier:
NCT01835587
First received: April 17, 2013
Last updated: May 31, 2017
Last verified: May 2017
April 17, 2013
May 31, 2017
July 18, 2013
November 13, 2016   (Final data collection date for primary outcome measure)
Maximum tolerated dose [ Time Frame: 30 months ]
To determine the maximal tolerated dose of oral Azacitidine in participants with AML or MDS after allogeneic HSCT
Same as current
Complete list of historical versions of study NCT01835587 on ClinicalTrials.gov Archive Site
  • Adverse Events [ Time Frame: 30 months ]
    Safety and tolerability of oral Azacitidine in this patient population
  • Acute and Chronic GVHD [ Time Frame: 30 months ]
    Incidence of acute and chronic GVHD
  • Time to discontinuation from treatment [ Time Frame: 30 months ]
    Duration of treatment until the occurrence of any of the events for treatment discontinuation
  • Pharmacokinetics - Cmax [ Time Frame: Day 1 of cycles 1 and 2 ]
    Maximum observed concentration in plasma
  • Pharmacokinetics - Tmax [ Time Frame: Day 1 of cycles 1 and 2 ]
    Time to first maximum concentration in plasma
  • Pharmacokinetics - AUC (0-t) [ Time Frame: Day 1 of cycles 1 and 2 ]
    Area under the plasma concentration-time curve from time zero to the last quantifiable time point
  • Pharmacokinetics - AUC (0-∞) [ Time Frame: Day 1 of cycles 1 and 2 ]
    Area under the plasma concentration-time curve from time zero to infinity
  • Pharmacokinetics - λz [ Time Frame: Day 1 of cycles 1 and 2 ]
    Terminal phase rate constant
  • Pharmacokinetics - t ½ [ Time Frame: Day 1 of cycles 1 and 2 ]
    Terminal half-life (t ½ )
  • Pharmacokinetics - CL/F [ Time Frame: Day 1 of cycles 1 and 2 ]
    Apparent total body clearance
  • Pharmacokinetics - Vd/F [ Time Frame: Day 1 of cycles 1 and 2 ]
    Apparent volume of distribution
  • Relapse Rate [ Time Frame: 30 months ]
    # of participants who relapse
  • Relapse Time [ Time Frame: 30 months ]
    Time to relapse
  • Overall survival at one year [ Time Frame: 12 months ]
    # of participants who survive
  • Relapse-free survival (RFS) at one year [ Time Frame: 12 months ]
    # of participants who survive without relapse
Same as current
Not Provided
Not Provided
 
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation in Subjects With Acute Myeloid Leukemia or Myelodysplastic Syndromes
A Phase 1/2 Dose and Schedule Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Oral Azacitidine (CC-486) in Subjects With Acute Myelogenous Leukemia and Myelodysplastic Syndromes After Allogeneic Hematopoietic Stem Cell Transplantation
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486 (also known as oral Azacitidine) in patients with AML or MDS after allogeneic HSCT. Allogeneic hematopoietic stem cell transplantation (HSCT) is more frequently used in Acute Myloid leukemia (AML) or Myelodysplastic Syndromes (MDS) as a potential curative therapy. However, disease recurrence/relapse and graft-versus-host disease (GVHD) remain the principal causes of fatal complications after transplantation. Azacitidine has significant activity in MDS and AML. Azacitidine has also demonstrated immunomodulatory activity in AML patients after allogeneic HSCT. An oral formulation of Azacitidine provides a convenient route of administration and an opportunity to deliver the drug over a prolonged schedule.
This is an open-label, multicenter study of oral Azacitidine in MDS or AML patients who have undergone allogeneic HSCT. The study consists of three phases: Screening, Treatment and Follow-up. During the Screening phase, which will take place within 4 weeks before starting oral Azacitidine, the study doctor will do tests to see if the patient is suitable for this study. The patient meeting protocol-specified entry criteria will enter the Treatment phase and be assigned to receive oral Azacitidine at 200 or 300 mg once daily (QD) for the first 7 or 14 days of each 28-day cycle. The dosing group of 200 mg QD on Days 1 to 7 will be evaluated first (ie, Cohort 1). In the event that unacceptable toxicity occurs in Cohort 1, then oral Azacitidine may be evaluated at lower dose levels (eg, 150 mg). If the dosing regimen is confirmed to be safe in Cohort 1, other cohorts will be evaluated sequentially. During the treatment phase, subjects will be monitored closely for safety and tolerability. Dosing interruption or delay, dose or schedule reduction, intra-subject dose/schedule escalation or re-escalation may occur on the basis of protocol-specified dosing adjustment guidelines. Safety will be monitored throughout the study at predetermined intervals and as clinically indicated by vital signs, physical examination, performance status, laboratory tests and evaluation of adverse events. The patient can continue to receive the study treatment for up to 12 months provided that they benefit from the study treatment and all protocol-specified criteria are met. However, the patient may receive the study treatment for less than 12 months due to adverse event, disease recurrence or progression. When the study treatment is discontinued, all patients who have received at least one dose of oral Azacitidine will be asked to see the study doctor for the Treatment Discontinuation visit. Thereafter, all patients discontinued from the study treatment will enter the Follow-up phase for safety and survival follow up.
Interventional
Phase 1
Phase 2
Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
  • Leukemia, Myeloid, Acute
  • Myelodysplastic Syndromes
Drug: Oral Azacitidine
Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary MTD is identified.
Experimental: Oral Azacitidine
Dose of 150mg, 200mg, or 300mg once daily (QD) for the first 7, 10, or 14 days of each 28-day cycle, starting 42-84 days after transplantation.
Intervention: Drug: Oral Azacitidine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
May 19, 2017
November 13, 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed (Myelodysplastic Syndromes) MDS or Acute Myeloid Leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (HSCT) with either peripheral blood or bone marrow as the source of hematopoietic stem cells

At the time of allogeneic HSCT:

  • No prior allogeneic HSCT; and
  • No more than 1 antigen mismatch at Human Leukocyte Antigen (HLA)-A, -B, -C, -DRB1 or -DQB1 locus for either related or unrelated donor; and
  • Bone marrow blast < 20% if MDS or ≤ 10% if AML; and
  • Peripheral blood blast ≤ 5%

Be able to start study therapy between 42 to 84 days following allogeneic HSCT

Post transplant bone marrow blast count ≤ 5% confirmed within 21 days prior to starting study therapy

Adequate engraftment within 14 days prior to starting study therapy:

  • Absolute Neutrophil count (ANC) ≥ 1.0 x 109/L without daily use of myeloid growth factor; and
  • Platelet count 75 x 109/L without platelet transfusion within one week.

Adequate organ function:

  • Serum aspartate transaminase (AST) and alanine transaminase (ALT) < 3 x upper limit of normal (ULN)
  • Serum bilirubin < 2 x ULN
  • Serum creatinine < 2 x ULN

Adequate coagulation (Prothrombin time [PT] ≤ 15 seconds, Partial thromboplastin time (PTT) ≤ 40 seconds, and/or International normalized ratio [INR] ≤ 1.5)

Have a negative serum pregnancy test (sensitivity of at least 25 mIU/mL at screening).

Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

Must agree to follow protocol-specified pregnancy precautions

Exclusion Criteria:

  • Use of any of the following after transplantation and prior to starting oral Azacitidine:

    • Chemotherapeutic agents for chemotherapy
    • Investigational agents/therapies
    • Azacitidine, decitabine or other demethylating agents
    • Lenalidomide, thalidomide and pomalidomide

Active Graft-versus-host disease (GVHD) grade II or higher

Any evidence of gastrointestinal (GI) GVHD

Concurrent use of corticosteroids equivalent of prednisone at a dose > 0.5 mg/kg

Known active viral infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV)

Active uncontrolled systemic fungal, bacterial or viral infection

Presence of malignancies, other than MDS or AML, within the previous 12 months

Significant active cardiac disease within the previous 6 months

Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom,   United States
 
 
NCT01835587
CC-486-AML-002
No
Not Provided
Not Provided
Celgene
Celgene
Not Provided
Study Director: Barry Skikne, M.D., FACP; FCP (SA) Celgene Corporation
Celgene
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP